For Booking details and registration fees, please email marketing@oxfordglobal.co.uk or visit

www.biotechinvestment-showcase.com

BIOTECH INVESTMENT SHOWCASE

22-23 May 2018, London, UK

Event Sponsors:

Industry speakers, investors and commercial speakers:

2018 Biotech Investor Showcase and Start-up Slam, 22nd - 23rd May 2018, London

The 2018 Biotech Investment showcase is the UK and Europe's most focussed and leading-edge funding,

investment and partnering forum in the biotech sector, hosting over 300 attendees. Leading VC funds,

pharma investors, hedge funds, emerging successful biotech spinoffs, early stage biotech discovery and

clinical companies as well as KOLs in the sector will be attending this one of a kind showcase event on

the 22nd & 23rd May 2018 in London. The event will help to identify the key technological and scientific

investment areas in the sector and will also offer a unique networking, partnering and business

development opportunity for those involved.

What does the showcase consist of?

Biotech Investment Conference Speakers, and Start up Slam Judging Faculty

Biotech Investment conference

programme and showcase

• An educational programme

with over 60 presentations,

postulating topics on scientific,

technological and investment

growth in the industry

• Over 50 biotech spinoffs,

early stage discovery and clinical

company product presentations

during the 2 days

• Two dedicated Startup Slam

Sessions and supported by a 20-

strong judging expert faculty

Networking opportunities &

scheduled business partnering

meetings

• Over 35 Scheduled business

partnering meetings

• Exhibition area with coffee

and lunch breaks

• Poster presentation

spotlights

• Pre-dinner reception and

networking drinks

Corporate Gala Dinner and

Awards

• Gala dinner and awards

ceremony featuring the best

scientist award categories

• Live polling throughout the

dinner on industry hot topics

• Supporting Cancer

Research UK through each event

evaluation form received

Start Up Slam

At the showcase event, there are two dedicated sessions on the agenda for start-up entrepreneurs or

scientists like yourselves to present your new product and research in front of leading pharma and

biotech venture companies, VCs and Technology Transfer offices.

If you are developing an innovative product or technology in the following areas, please email

info@oxfordglobal.co.uk

• NGS/Single Cell/Genomics Technologies/dPCR/Microfluidics

• Microbiome Discovery and Development

• Artificial Intelligence and Digital Health

• Immuno-Oncology and Immuno-Therapy

• Biomarkers/Precision Medicine/ Liquid Biopsy

Lori L. Badura,

EMD Serono

Melanie Goward

Maven Capital Maciek Drozdz,

Johnson & Johnson Bent Jakobsen,

Immunocore Olga Krylova

Pfizer Mouad Lamrani

Menicon Co., Ltd

Anne Goubier

Tusk Therapeutics Timothy Herpin

Astra Zeneca Torsten Hoffmann

Silence

Therapeutics

Olga Kubassova,

IAG

Tony Hickson

Imperial Innovations

Ltd

Avi Spier

Novartis

John Haurum

F-star

Tim Kievits

VitrOmics Rakesh Dixit

Medimmune

Philip Arlen

Precision Biologics

Peter Dudek

Wellington Partners

Kristin Wannerberger

Ferring

Conference and commercial speakers Includes:

• Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer

• Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment, Medimmune

• Morten Lindow, Director, Innovation and Project Excellence, Roche

• Ro Wickramasinghe, Director of Oncology Evaluation, AstraZeneca

• Bent Jakobsen, Chief Scientific Officer, Immunocore

• Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A

• Bernhard Paetzold, Founder, S-Biomedic

• Mouad Lamrani, Director of R&D Innovation Center, Menicon Co., Ltd

• Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics

• Tommi Lehtonen, CEO, Blueprint Genetics

• Davide Danovi, Director, Centre for Stem Cells & Regenerative Medicine, King's College London

• Patrice Garnier, CEO, AMABIOTICS

• Patrick Gillevet, Professor, Director, George Mason University, Director of the Microbiome Analysis Center

• Andreas Kungl, CEO, Antagonis

• Assaf Oron, Chief Business Officer, BiomX

• David Llewellyn, CEO, DJS Antibodies

• Ron Alfa, VP of Discovery and Product, Recursion Pharmaceuticals

• Mihriban Tuna, Vice President, Drug Discovery, F-star Biotechnology Ltd.

• John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.

• Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.

• Fred Jacobs, CEO, TYG Oncology

• Imke Mulder, Research Director, 4D Pharma Research Ltd

• Xavier Duportet, CEO, Eligo Bioscience

• Leonardo Rodrigues, Associate Director - Advanced Analytics, BERG

• Rajiv Gogna, Co-Founder & CEO, Resurgo Genetics

• Anne Goubier, VP Immunology, Tusk Therapeutics

• Sowmiya Moorthie, Senior Policy Analyst (Epidemiology), PHG Foundation

• Mohammed Kamran, CEO & Medical Director, Future Genetics

• Christopher Primiano, Senior Vice President, Operations, Business Development, Karyopharm Therapeutics

• Marko Lehes, Founding CEO, SelfDiagnostics

• Edward Green, Chief Executive, CHAIN Biotechnology Ltd

• Tina Flatau, Managing Director, MedAnnex

• Mike Karim, CEO, Oxford Endovascular Limited

• Keith Errey, CEO, Isansys

• Will Dracup, CEO, Biosignatures

• Romain Micol, President, CEO, Co-Founder, Combined Therapeutics

• Stephen B. Parker, Chairman, Sareum Holdings plc

• Sandy Primrose, Non-Executive Chairman, Urosens

• Janusz Dutkowski, Founder and CEO, Data4Cure Inc

• Heinrich Roder, CTO, Biodesix

• Caroline Barelle, CEO, Elasmogen

• Aviv Boim, CEO, Tikcro Technologies Ltd

• Olga Kubassova, Chief Executive Officer, IAG

• Tim Kievits, Director Healthcare Innovation, VitrOmics Healthcare Holding B.V.

• Hugh Ilyine, CEO, DestiNA Genomics

• Stuart Hassard, Chief Scientific Officer, deltaDOT Ltd

Investors, Pharma Ventures and Alliance speakers:

• Peter Dudek, Principal, Wellington Partners Life Science Venture Capital

• Stephan Christgau, Investment Director, Novo Seeds

• Christina Takke, Managing Partner, V-Bio Ventures

• Daniel Oliver, CEO, Capital Cell

• Oskar Slotboom, Partner, BGV

• Gerard Honing, Translational Research Manager, Crohn's & Colitis Foundation

• Patrik Frei, Founder and CEO, Venture Valuation AG

• Felice van Weegen, Investment Associate, LSP Life Sciences

• Michael Anstey, Investment Director, Cambridge Innovation Capital

• Hakim Yadi, CEO, Northern Health Science Alliance

• Savvas Neophytou, Partner, Head of Life Sciences, Deepbridge Capital LLP

• Piyush Unalkat, Head of Unit – Equity Investments, European Investment Fund

• Melanie Goward, Investment Director, Maven Capital

• Vijay Barathan, Life Science Partner, Catapult Ventures

• Tony Hickson, Managing Director, Imperial Innovations Ltd

• Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management, EMD Serono

• Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation

• Avi Spier, Director, NIBR BD&L, Search and Evaluation, GNF Systems and Microbiome, Novartis (Reserved)

• Timothy Herpin, Vice President, Head of Transactions Business Development, AstraZeneca

• Keith Woodhouse, Partner, Fieldfisher

• Simon Haworth, CEO, Dynastybio

• Irina Haivas, Principal, GHO Capital Partners

DAY 1 – Stream 2

Microbiome Discovery and Development

➢ Machine learning and Data Analysis

➢ AI application in Pharma R&D

➢ Genomics, Big Data Analysis and Deep Learning

➢ AI and Precision medicine

➢ AI, Robotics and Machine Learning: leading data science and

machine learning

➢ Integrated Healthcare and Digital health

➢ Medical devices development for Cardiovascular, and

Neurovascular Diseases

➢ Medical Diagnostics

➢ Digital healthcare solutions

DAY 1 – Stream 1

NGS/Genomics Technologies/dPCR/Microfluidics

DAY 1 – Stream 3

Pharma Technologies, Artificial Intelligence, Medical Devices

and Digital Health

➢ Innovations of NGS in pharma: biomarker development,

precision medicine and clinical diagnostics

➢ NGS, genomics and clinical diagnostics in healthcare

➢ NGS Data Analysis & NGS Application Strategies

➢ Single Cell ‘Omics Analysis: Current and Emerging Tools

➢ Single Cell Analysis - Translation to Diagnostic and Therapeutic

Applications

➢ Single Cell Data Analysis & Advances in Microfluidic

Technologies

➢ Microbiome Discovery & Technologies

➢ Translational Science of the Microbiome

➢ Novel Genomic Technologies

➢ Next Generation Sequencing technologies

➢ Data Management in Microbiome Discovery

➢ Bacterial Pathogens and the Microbiome

➢ Small Molecule Microbiome Discovery

➢ Discovery and development of Microbiome Therapeutics in

Metabolic Disorders, Inflammatory Conditions, Women’s

Health, Dysbiosis

➢ Immune monitoring

➢ Clinical trial design and management

➢ Translational biomarkers

➢ Microbiome and Immuno-oncology

➢ Cancer Immunoassays for biomarker development

➢ CAR T Cell Therapy

➢ Immuno-oncology Therapeutic Development

DAY 2 – Stream 1

Immuno-Oncology and Immuno- Therapy – Discovery and

Development

➢ Precision Medicine, Companion Diagnostics, Molecular

Diagnostics Development

➢ Innovations in Biomarkers Research, Assay

Development, Imaging, Data Integration Methods,

Bioinformatics, Trial Design

➢ Molecular Diagnostics Development

➢ Genomic approaches in drug development

➢ Advances made in NGS techniques in liquid biopsy

➢ RNAseq NGS in biomarker benchmarking

Day 2 - Stream 2

Proteins, Antibodies, Regenerative Medicine Discovery and Development

Gain insights and learn from over 60 expert speakers from pharmaceutical, biotech, academic, medical devices and

investment companies

Assessing the potential of artificial intelligence in drug discovery and development, machine learning and patient monitoring

Learn about the latest medical devices development in Neurovascular, Cardiovascular and Cancer related diseases

Benefit from updates in Protein, Antibodies, Peptides and Cell based biotherapeutic development

Maximising your knowledge on the key discovery and development strategies in Immunotherapy, Immuno-oncology, Biologics

and Microbiome

Identifying the key technologies in accelerating the genomics revolution

Exploiting Biomarker technologies in clinical development, precision medicine and diagnostics development

Evaluating and overcoming the challenges of finding and funding innovation for Biotech spinoffs

Gaining insights from the Partnering and Licensing Innovations in the Pharma & Biotech industry

Attendee Benefits

Do not miss out on presenting on the speaker programme, featuring presentations by:

✓ Emerging university spin offs and entrepreneurial companies to access to interested VC funds and investors

✓ Academic researchers and technology transfer offices to present an IP or idea to funding and development partners

✓ Biotech companies to partner their products, form alliances and develop global financing contacts

For speaking opportunities, please email c.roberts@oxfordglobal.co.uk

➢ Advancing to the clinic: antibody drug conjugates

➢ Innovative design and engineering approaches

➢ Fusion protein therapeutics

➢ New targets & new indications for protein biotherapeutics

➢ Accelerating antibody discovery & optimisation:

➢ Stem Cell Research

➢ Cell and Gene Therapy

DAY 2 – Stream 3

Biomarkers/Precision Medicine/ Liquid Biopsy in Drug and

Clinical Development/Molecular Diagnostics Development

08.00-08.30

Keynote Address- Addressing R&D Innovation

• Therapeutic areas in focus

• Partnering and open innovation

Sponsored by:

08.30-09.00

Panel Discussion - Artificial Intelligence and Digital Health

• Analysis of the Artificial Intelligence market: Drug Discovery and Development, Machines Learning and Patient

Monitoring

• Digital healthcare and integrated healthcare

• Innovation – clinical validation, market access and scale up in the UK

Panellists: Vijay Barathan, Life Science Partner, Catapult Ventures

Felice Verduyn - van Weegen, Investment Associate, LSP Life Sciences

Leonardo Rodrigues, Associate Director - Advanced Analytics, BERG

Ron Alfa, Vice President, Discovery & Product, Recursion Pharmaceuticals

Hakim Yadi, CEO, Northern Health Science Alliance

09.00-09.30

Panel Discussion - Accelerating Genomics Revolution

• Adoption of NGS

• Moving to single-cell biology

• Clinical Diagnostics

• cell-free DNA

• dPCR

• Microfluidics

Panellists:

Torsten Hoffmann, Chief Operating Officer, Silence Therapeutics

Sowmiya Moorthie, Senior Policy Analyst, PHG Foundation

Tommi Lehtonen, CEO, Blueprint Genetics

EMD Serono

09.30-10.00

Panel Discussion - Innovation in the Pharma & Biotech – Partnership Strategies

• Innovation in practice – how partnerships are formed in Pharma

• The latest drug research and development efforts, success and paths to commercialisation

• Realising the true value of academic-industry collaboration

• Playing to your strengths - early-stage technology collaborations

Panellists:

Olga Krylova, Senior Director, Global Scouting, UK, External Science & Innovation, Pfizer

Stephen B. Parker, Chairman, Sareum Holdings plc

Olga Kubassova, Chief Executive Officer, IAG

10.00-10.30 Morning Refreshment Break

Stream 1: NGS/Genomic

Technologies/dPCR/ Microfluidics

Stream 2: Drug Discovery and

Development – Microbiome,

Immuno-oncology, Oncology

Stream 3: Pharma IT, Artificial

Intelligence, Medical Devices,

and Digital Health

Scheduled Partnering

Meetings x8 and

Exhibition

10.30-10.45 Laura Roca-Alonso, Chief Business

Officer, Silence Therapeutics

Alex Blyth, CEO, LiftBioSciences

AI And Variant Classification In

Rare Disorder Diagnostics

Tommi Lehtonen, CEO, Blueprint

Genetics

DAY 1 Agenda At A Glance

10.45-11.00

Spinoffs and emerging biotech

company presentation

New Generation of Therapeutic

and Intelligent mRNA

Romain Micol, President, CEO,

Co-Founder, Combined

Therapeutics

Decoding 'Junk' DNA: An AI

Approach To Novel

Therapeutics

Rajiv Gogna, Co-Founder & CEO,

Resurgo Genetics

11.00-11.15

Jerome Dubos, Business Developer,

DNA Script

Aviv Boim, CEO, Tikcro

Technologies Ltd

Spinoffs and emerging biotech

presentation

11.15-11.30

Spinoffs and emerging biotech

company presentation

Spinoffs and emerging biotech

company presentation

Spinoffs and emerging biotech

presentation

11.30-12.00 Panel Discussion: Microbiome Discovery and Development

• What are the most successful microbiome trends with clear therapeutic potential?

• What are the potential challenges of microbiome drug development?

• Playing to your strengths - early-stage technology collaborations

Moderator:

Panellists:

Maciek Drozdz, Principal of Venture Investments, Johnson and Johnson Development Corporation

Kristin Wannerberger, Director R&D Alliance Management, Ferring International Center S.A

Bernhard Paetzold, Founder, S-Biomedic

Patrick Gillevet, Professor & Director, Department of Biology and MicroBiome Analysis Center, George

Mason University

Xavier Duportet, CEO, Eligo Bioscience

Spinoffs and emerging biotech company presentation

Spinoffs and emerging biotech presentation

12.00-12.30 Machine Learning and Sequence Analysis As Enablers Of RNA Drug Discovery

Morten Lindow, Director, Innovation and Project Excellence, Roche

Stream 1: NGS/Genomic

Technologies/dPCR/ Microfluidics

Stream 2: Drug Discovery and

Development – Microbiome

Stream 3: Pharma

Technologies, Artificial

Intelligence, Medical Devices,

and Digital Health

12.30-13.30 Lunch

13.30 – 14.00

Single Cell Analysis - Translation

To Diagnostic and Therapeutic

Applications

Microbiome Discovery and

Development

Edward Green, Chief Executive,

CHAIN Biotechnology Ltd

AI and Precision medicine

Ron Alfa, Vice President,

Discovery & Product, Recursion

Pharmaceuticals

Scheduled Partnering

Meetings x9 and

Start Up Slam

DAY 1 Agenda at a Glance

14.00 – 14.30 Immunosequencing - Enhancing

Immunotherapy discovery and

Development

M. Allen Northrup CEO, MIODx

(TBC)

From Microbiome

Explorations to Effective

Innovative Therapies in

Parkinson Disease: a case

study

• From biochemical

mechanisms to proof of

concept: how to design a

new microbiome-oriented

strategy for Parkinson

Disease;

• Preclinical and clinical trials:

the same road as

pharmaceutical

development?

Patrice Garnier, CEO,

AMABIOTICS

Machine Learning and Data

Analysis

Leonardo Rodrigues, Associate

Director - Advanced Analytics,

BERG

14.30 – 15.00 Collaborative Phenotyping at

King’s College London: HipSci and

the Stem Cell Hotel • Characterisation of a large panel of

Human Induced Pluripotent Stem

Cells (see www.hipsci.org)

• Integration of High Content imaging

with other datasets such as genomics,

transcriptomics, proteomics

• Opening of a collaborative

phenotyping space to internal and external scientists and technology

providers Davide Danovi, Director, HipSci

Cell Phenotyping, Centre for Stem

Cells & Regenerative Medicine,

King's College London

Microbiome and Drug

Discovery in Ferring • The Human Microbiome

Translational Research

Program

• Bacteriophages

Kristin Wannerberger,

Director R&D Alliance

Management, Ferring

International Center S.A

Medical Devices And Digital

Healthcare Solutions

Marko Lehes, Founding CEO,

SelfDiagnostics

15.00 – 15.30 NGS, Genomics And Clinical

Diagnostics In Healthcare

Customized phage therapies

that target and destroy

harmful bacteria in chronic

diseases such as

inflammatory bowel disease

(IBD) and cancer

• Growing evidence in chronic

diseases such as IBD

and colon cancer of need

for targeted eradication of

harmful bacteria present in

the microbiome

• BiomX discovers and

validates proprietary

harmful bacterial targets

and customizes natural and

engineered phage

compositions against these

targets

• BX002, a novel customized

phage therapy for IBD

expected to enter clinical

trials in 2019

Assaf Oron, Chief Business

Officer, BiomX

Digital Health Case Study

Keith Errey, CEO, Isansys

DAY 1 Agenda at a Glance

15.30 – 16.00 NGS, Genomics And Clinical

Diagnostics In Healthcare

• Exploration of the current British

clinical practice landscape and

genomics

• Gaining buy-in from NHS and

the public: challenges around

consent and data sharing

• The promise of NGS and the

(significant) barriers associated to

that delivery

• Delivering the Promise: The

consequence of differing outcomes

for patients & society

Mohammed Kamran, CEO & Medical

Director, Future Genetics

Microbiome Drug

Development Case Study

Imke Mulder, Research

Director, 4D Pharma Research

Ltd

Artificial Intelligence and

Precision Medicine

Janusz Dutkowski, Founder and

CEO, Data4Cure, Inc

16.00-16.30 Afternoon Refreshments

16.30-17.00

Panel Discussion: Join Our Panellists As They Address The Challenges Of Finding And Funding Innovation For Biotech

Spinoffs

• De-risking biotech projects in the university environment prior to spinout or licence – a good or bad idea?

• The importance of patient capital for early stage biotech investments

• Other models of funding therapeutic development projects (e.g. Licensing funds and project aggregators)

Moderator:

Tony Hickson, Managing Director, Imperial Innovations Ltd

Panellists:

Stephan Christgau, Investment Director, Novo Seeds

Tina Flatau, Managing Director, MedAnnex

Gerard Honing, Translational Research Manager, Crohn's & Colitis Foundation

Michael Anstey, Investment Director, Cambridge Innovation Capital

17.00 – 17.30 Panel Discussion: Other Financing Opportunities for Innovation

• Viewpoints on investment landscape and investor sources

• Ensuring mutually beneficial incentives

• Terms and deal structures

• Collaboration and syndication

For - Angel investment options

For - Private Financing options

For - Venture Capital options

For – Seed Investors

Panellists:

Christina Takke, Managing Partner, V-Bio Ventures

Daniel Oliver, CEO, Capital Cell

Oskar Slotboom, Partner, Biogeneration Ventures

Piyush Unalkat, Head of Unit – Equity Investments, European Investment Fund

Savvas Neophytou, Partner, Head of Life Sciences, Deepbridge Capital LLP

17.30-18.00 Panel Discussion – Medical Devices Development for Cardiovascular, And Neurovascular Diseases

• Trends and innovations of the medical device manufacturing

• Regulatory requirements

• What are investors looking for?

• Communicating with key stakeholders

Panellist: Mike Karim, CEO, Oxford Endovascular Limited

18.00-18.30 Drinks Reception and Sponsored Awards Dinner

END OF DAY ONE

DAY 1 Agenda at a Glance

08.00-08.30

Keynote Address – Biomarker Clinical Market Development, Companion Diagnostics Development And

Targeted Therapy

08.30-09.00 Panel Discussion – Accelerating Antibody Discovery & Optimisation:

• Bispecific antibodies

• Monoclonal antibodies

• Antibody drug conjugates

Panellists:

Mihriban Tuna, Vice President Drug Discovery, F-star Biotechnology Ltd

David Llewellyn, CEO, DJS Antibodies

09.00-09.30

Panel Discussion – Precision Medicine - Biomarkers and Diagnostics in Targeted Patient Therapy

Panellists:

Lori L. Badura, Director, Evaluation and Licensing, Global Business Development and Alliance Management Healthcare Business, EMD Serono

Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.

Tim Kievits, Director Healthcare Innovation, VitrOmics Healthcare Holding B.V.

09.30-10.00

Special Address: Updates on Immuno-Oncology Discovery and Development Trends

Rakesh Dixit, Vice President, Research & Development, Global Head, Biologics Safety Assessment, MedImmune

10.00-10.30 Panel Discussion -Harnessing Innovation and Funding in Digital Healthcare and Digital Biology Companies

• Financing and investment considerations

• Discovery and moving to the clinic – challenges and opportunities

• Overcoming hurdles on regulation, reimbursement and pricing

Panellists:

Simon Haworth, CEO, Dynastybio

Michael Heltzen, CEO, BlueSeq Innovations(TBA)

Irina Haivas, Principal, GHO Capital Partners

Keith Woodhouse, Partner, Fieldfisher

10.30-11.00 Morning Refreshment Break

Stream 1: Drug Discovery

and Development -

Immuno-Oncology and

Immuno-Therapy

Stream 2: Proteins,

Antibodies, Regenerative

Medicine Development

Stream 3:

Biomarkers/Precision

Medicine, Diagnostics ,

Liquid Biopsy in Drug

Development

Scheduled Partnering

Meetings x8 and

Exhibition

11.00-11.15 Fred Jacobs, CEO, TYG

Oncology

Birgit Werner, Managing Director,

UGIsense

Will Dracup, CEO,

Biosignatures

11.15-11.30 Michael J. Natan, Ph.D.

Chief Executive Officer

Ultivue Inc.

Cyto-Mine®: a novel single cell

analysis platform for rapid

biopharmaceutical discovery and

cell line development

Frank Craig, CEO, Sphere Fluidics

Milan Bhagat

TriStar Technology Group

LLC (Reserved)

11.30-11.45 Spinoffs and emerging

biotech company

presentation

Spinoffs and emerging biotech

company presentation

Spinoffs and emerging

biotech company

presentation

DAY 2 Agenda At A Glance

11.45-12.00

Spinoffs and emerging

biotech company

presentation

Spinoffs and emerging biotech

company presentation

Spinoffs and emerging

biotech company

presentation

12.00-12.30 Panel Discussion – Market Outlook for Immuno-oncology investment

Recent Deal Trends In Immuno-Oncology

• From the Biotech perspective: funding environment, partnerships and exits

• From the Pharma side: deal trends and emerging innovation

• Strategies and tactics for combination therapies

Moderator:

Timothy Herpin, Vice President, Head of Transactions, Business Development, AstraZeneca

Panellists:

John Haurum, CEO, F-star GmbH & F-star Biotechnology Ltd.

Ro Wickramasinghe, Director of Oncology Evaluation, AstraZeneca

Peter Dudek, Principal, Wellington Partners Life Science Venture Capital

Anne Goubier, VP Immunology, Tusk Therapeutics

12.30-13.30 Lunch

Stream 1: Drug Discovery

and Development -

Immuno-Oncology and

Immuno-Therapy

Stream 2: Proteins,

Antibodies, Cell Therapeutic

Development

Stream 3:

Biomarkers/Precision

Medicine, Diagnostics,

Liquid Biopsy in Drug

Development

Scheduled Partnering

Meetings x9 and Start

Up Slam

13.30-14.00 Immuno-oncology

Therapeutic Development

Senior Representative,

Mologen(Reserved)

soloMER™ Biologics;

developing site-specific

therapeutics for

inflammatory disease

Caroline Barelle, CEO,

Elasmogen

Precision Medicine And The

Role of Biomarkers in

Clinical Development

Philip M. Arlen, President &

Chief Executive Officer,

Precision Biologics, Inc.

14.00 – 14.30

ImmTAC® Reagents:

Novel Bi-Functional TCR-

Based Biologics for

Targeted Immunotherapy

Bent Jakobsen, Chief

Scientific Officer, Immunocore

Using High Performance

Capillary Electrophoresis in

the Analytical steps of a

MonoClonal Antibody's life. • Optimising production work

flows by fast accurate analytics.

• Testing stability throughout the

production process and

delivery to point of care.

• Monitoring the efficacy of the

product at the point of care

Stuart Hassard, Chief Scientific

Officer, deltaDOT Ltd

Machine Learning and

Biomarkers

Matthew Hall,

CEO, Co-founder

SimplicityBio SA (Reserved)

14.30 – 15.00 Car T Cells For The

Treatment Of Cancer

GAGbodies: a new class of

biotherapeutics targeting

glycans in immuno-

oncological indications

Andreas Kungl, CEO, Antagonis

Apostle - Enabling the New

Landscape of Liquid Biopsy

• The liquid biopsy

technology - central topic

of precision medicine, a

multi-national strategic

roadmap for the global healthcare.

• The current liquid biopsy

technologies suffer from

suboptimal sensitivity and

specificity.

• Innovative Apostle MiniMax

and Triton technologies,

combining nanotechnology

and artificial intelligence

and improving the

efficiency and accuracy of

liquid biopsy

David Ge, CEO & President,

Apostle Inc

15.00 – 15.30 IO on the Move: New

Targets, New Trends, New

Combinations

Stem Cell Cancer Discovery

and Development

Sandy Primrose, Non-Executive

Chairman, Urosens

Direct, PCR free detection of

microRNAs – A transformation

for RNA biomarker diagnosis

Hugh Ilyine, CEO, DestiNA

Genomics

15.30 – 16.00 Afternoon Refreshments

16.00-16.30 Immuno-oncology

Therapeutic Development

Anne Goubier, VP

Immunology, Tusk

Therapeutics

Therapeutic antibodies to

GPCRsDJS Antibodies’

technology for the discovery of

high quality mAbs to GPCRs

• Case study – oncology

• Future pipeline development

David Llewellyn, CEO, DJS

Antibodies

Diagnostics Development

Heinrich Roder, CTO, Biodesix

16.30 – 17.00 How to value a Biotech Start-up company

What’s important when speaking about valuation (pre-money / post money)

• Overview of valuation approaches

• Valuation of a therapeutic Biotech product (incl. example)

• Conclusion

Patrik Frei, Founder and CEO, Venture Valuation AG

END OF SHOWCASE

BOOKING FORM HOW TO REGISTER:

FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: marketing@oxfordglobal.co.uk

Please complete fully and clearly. Please photocopy for additional delegates Title: …………………………… Forename: ………………………………………………….. Surname: …………………………………………………... Company/Organisation: …………………………………………………………………………………………………………………………………………. Job Title: …………………………………………………………………………………………………………………………………………………………... Address: ……………………………………………………………………………………………………………………………………………………………. Postcode: …………………………... Country: …………………………... Direct Telephone: ………………………………... Mobile: …………….…………….. Switchboard: ……………………….. Fax: ……………………….. Email: ……………………………………………………………………………………………………………………………………………………………….. Signature: ………………………………………………. Date: ……………………………………………………..

Number of delegates:

CREDIT CARD: Visa MasterCard Maestro Amex Credit Card Number:

Valid from: /

Expiry Date: /

Security code:

Cardholders name ………………………………………...

Signature: …………………………………………………. Date: ……………………………………….

PLEASE INVOICE ME:

Invoice Address (if different from above) ……………………………………………………………………… ……………………………………………………………………… ……………………………………………………………………... PO Number (if applicable) ………………………………………. * Please note there is a £50 plus VAT handling charge for payment via invoice * All card payments will be subject to a 3% bank charge or 4% AMEX charge * Payment to be made within 30 days of invoice

Registration Fees

Delegate Details

How to Pay (choose one of the following payment options)

I would like to attend: (Please tick as appropriate) REGISTRATION AND PARTNERING ACCESS (FULL PASS) • Full access to the 1-2-1 networking portal pre-event • Up to 17 Meetings per day (34 meetings over 2 days) • 1x full conference pass

Academic Spinoffs, Biotech spinoffs, TTOs: £950+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £2450+VAT POSTER PRESENTATION • 1x A0 portrait poster display in exhibition hall (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs:

£150+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £250+VAT SPEAKER PRESENTATION • 15 Minute presentation platform in conference room (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs: £250+VAT

VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors, Solution Providers: £1000+VAT EXHIBITION • 2x2m table-top in main Exhibition Hall (must register for full pass)

Academic Spinoffs, Biotech spinoffs, TTOs:

£500+VAT VC Funds, Pharma Ventures, Investors, Pharma & Biotech Investors,

Solution Providers: £1000+VAT

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk www.biotechinvestment-showcase.com

Terms & Conditions of Booking

I agree to the terms and conditions (Please refer to page 2 for the terms and conditions)

To obtain information on our full sponsorship opportunities, please contact marketing@oxfordglobal.co.uk

Sponsorship Opportunities

Terms & Conditions of Booking

1. Definitions In these terms and conditions, the following terms have the following meanings: - “Contract Price” The total cost payable for the Package as shown on the official booking form “Delegate/Sponsor” Any person who has been invited by the Organisers to attend the showcase, start up slam and partnering meetings OR Any company or person who has purchased a package or any agent representative or employee of such company or person “Event” named in the Terms and Conditions Title above "Meeting Area" The meeting area/exhibition space designated for the Sponsor/Exhibitor at the Event “Organisers” Oxford Global Marketing Limited “Package” The accommodation, area for meetings and conference sessions in a hotel venue where the Event will take place in-cluding meals but not beverages unless specified by the Organiser. 2. Law These terms shall be construed in accordance with English law and subject to the exclusive jurisdiction of the English courts. 3. Application for Packages Applications must be made on the Organiser’s official booking form, which must be completed in full. The Organisers may accept applications in writing, by email or facsimile, or accept a deposit payment in lieu of written application at their sole discretion, and on the understanding that these terms and conditions apply to any application and supersede any terms and conditions of the Delegate/Sponsor. Any alterations of these terms and conditions cannot be accepted without the prior written consent of a direc-tor of the Organiser. 4. Payment The Delegate/Sponsor shall pay the contract price in accordance with the dates set out in the official booking form. If any of the above payments shall be 30 days in arrears whether demanded or not, the contract may at any time thereafter be terminated forthwith by the organisers by notice in writing to these parties. Upon termination all instalments paid shall be forfeited and the balance shall become immediately payable. Such termination shall not prejudice any rights or claims by the Organisers against these parties in respect of any prior breach. 5. Contract and Termination On the acceptance of the official booking form by the Organisers, a contract relating to the package purchased by the Delegate/Sponsor will exist between these parties and the Organisers as set out in these terms and conditions. In case of non payment of any sum due from these parties whether legally demanded or not, or of the breach, or non-observance, by these parties of any of these terms and conditions, or any regulations to be observed by these parties, the Organisers shall have the right to terminate the contract and to remove and exclude these parties from the Event without prejudice to the right to recover all sums payable by these parties and all other claims against it, and any loss of damage sustained by the Organisers. 6. Withdrawal or Cancellation In the event of withdrawal or cancellation, the following amounts shall become immediately payable: More than 6 months prior to the event 35% cancellation fee Between 6 and 3 months prior 75% cancellation fee Less than 3 months prior to the event full cancellation fee Any notification of withdrawal or cancellation must be in writing and sent to the Organisers by recorded delivery. Cancellation will be deemed to have occurred when written notification has been received by the Organisers. 7. Occupation of Meeting Area The Delegate/Sponsor (subject to contracted package) must occupy their allocated Meeting Area by the Event opening time on the first day of the Event. Failing to do so will be deemed a cancellation of Package, in which case the terms and conditions relat-ing to withdrawal or cancellation will apply, and the Package may be offered to another Delegate/Sponsor. 8. Bankruptcy In the event of bankruptcy, liquidation, having an administrator or receiver appointed, or entering into a voluntary arrangement with its creditors; the Delegate/Sponsor’s contract may be terminated at the option of the Organisers and the full contract price will be due and payable forthwith. 9. Prohibition of Transfer A Delegate/Sponsor may not assign, sublet or share possession of, or grant licenses in respect of the whole or any part of the Package nor may any cards, advertisements, or printed matter of firms who are not bona fide Delegate/Sponsor’s be exhibited in or distributed from any area. This does not apply to firms which are subsidiaries, agents or principals of the Solution Provider and which are duly listed on the official application form at the time of booking.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk

Terms & Conditions of Booking

10. Postponement or Abandonment The Delegate/Sponsor shall not have any claim against the Organisers in respect of any loss or damage consequent upon the failure for whatever reason to hold any part of the Event or if the hotel venue at which the Event is scheduled to take place be-comes wholly or partially unavailable for the holding of the Event. If, by the re-arrangement or postponement of the period of the Event, or by substitution of another hotel venue for the holding of the Event, or any other reasonable action, the Event can take place, the contract shall remain in force. If the Organisers abandon the Event other than by reason of events or circumstances beyond its reasonable control, the Organisers will reimburse the Contract Price. If the Event is abandoned by the Organisers by reason of events or circumstances beyond it’s reasonable control, the Organiser will reschedule the Event (to be held within 12 months of the original event) but no reimbursement will be made by the Organiser and the Delegate/Sponsor will remain liable to pay the Contract Price. 11. Liability Save in the case of death or personal injury caused by the Organisers' negligence, the Organisers are not responsible for the health & safety of any meeting or conference or any property of the attendees or any third party, or for any loss or damage sus-tained by these parties or any third party, in each case for any reason whatsoever. Delegates/Sponsors should have in place their own insurance to cover all such liabilities and risks. 12. Event Promotional Materials Only the signage provided by the Organisers will be used by the Delegate/Sponsor. The Organisers will notify the Delegate/Sponsor of the nature of available meeting facilities and of promotional material e.g. display stands and brochures that they may display. The Organisers reserve the right (without being required to give notice) to alter the layout of any meeting floor plan at any time and to relocate these parties to another area. 13. Information and Copyright Information supplied by the Organisers in relation to any event is accurate to the best of their knowledge and belief, but shall not constitute any warranty or representation by the Organisers and any inaccuracy or mistake in such information or omission from it shall not permit the Delegate/Sponsor to cancel a confirmed booking. All information and data relating to the Event, which is supplied by the Organisers to the Delegate/Sponsor is the copyright of the Organisers and cannot be passed on to any third party for any purpose. The Organiser processes information about each Delegate/Sponsor in accordance with the Organiser's privacy policy, a copy of which is available on our website or by written request. By submitting information to the Organiser, the Delegate/Sponsor con-sents to such processing and warrants that all data provided is accurate 14. Substitution The Delegate/Sponsor may substitute a representative up to 3 weeks before the event provided that this is conveyed via email to the Organiser and also by completing a new on-line application form and stating in the relevant box on the form the name of the person s/he is replacing. The replacement Delegate/Sponsor will take over the partnering meetings agreed by the original party, although these can be cancelled if the meetings are no longer relevant. 15. Photography/ Video Photography For promotional purposes, there may be professional photography and video production taking place during the conference. Del-

egates who do not wish to be filmed or recorded should advise the organisers by email to operations@oxfordglobal.co.uk, prior to the event.

If you have any further queries please call the marketing team on +44(0)1865 248455 or email marketing@oxfordglobal.co.uk